Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene and SpringWorks Form MapKure to Test B-RAF Inhibitor in Solid Tumor Cancers

publication date: Jun 18, 2019

Beijing's BeiGene and SpringWorks Therapeutics of Stamford, Connecticut have joined to form MapKure, which will initially be in charge of non-Asia clinical development of BeiGene's B-RAF inhibitor. SpringWorks will contribute cash to MapKure, while BeiGene will own a majority stake in the company in return for a global royalty and milestone-bearing license to develop and commercialize BGB-3245 outside of Asia (but including Japan). B-RAF mutations are thought to cause the growth of several solid tumor cancers.

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.